IMPLICATIONS FOR PATIENT CARE: [18F]CTT1057 could expand access to PSMA radiotracers for the detection of prostate cancer lesions in patients at first BCR, a population frequently misdiagnosed or underdiagnosed in clinical practice. This evidence concerns the gene FOLH1 and prostate cancer.